In his weekly clinical update, Dr. Griffin informs us about the World Health Organization research and development plan to combat endemic pathogens including hepatitis C virus, RSV and dengue virus, another case of mpox in Britian, the Marburg virus outbreak in Rwanda, before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, if there is a benefit to additional COVID vaccinations after the initial series, ISDA guideline for using anti-SARS-CoV-2 monoclonal antibody therapy for prophylaxis, where to find PEMGARDA, a reminder of how and when to use steroids to treat COVID-19, if and how do severe secondary bacterial infections develop following SARS-CoV-2 infection, and if COVID-19 associates with a risk of autoimmune and autoinflammatory connective tissue disorders. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Is the WHO the world’s NIH: endemic pathogens initiative (eBioMedicine) Another two cases of mpox in Britian (Reuters) How to stop Marburg virus (Rwanda Biomedical Centre) Marburg Virus fact sheet (Rwanda Biomedical Centre) Influenza weekly surveillance report: cliff notes (CDC FluView) RSV NETwork (CDC RSV) Respiratory virus activity (CDC Respiratory Illnesses) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Symptom reduction after additional vaccine dose during Omicron (OFID) IDSA Guideline update for SARS-CoV-2 monoclonal antibody pemivibart pre-exposure prophylaxis (CID) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Fusion center near you….if in NY (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Infectious Disease Society guidelines for treatment and management (ID Society) Drug interaction checker (University of Liverpool) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC) Managing healthcare staffing shortages (CDC) Steroids, dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Secondary bacterial infection follows COVID-19 (Nature Communications) Daniel Griffin’s evidence-based medical practices for long COVID (OFID) Autoimmune and autoinflammatory connective tissue disorders following COVID-19 (JAMA Dermatology) Letters read on TWiV 1164 Dr. Griffin’s COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv
In his weekly clinical update, Dr. Griffin informs us about the World Health Organization research and development plan to combat endemic pathogens including hepatitis C virus, RSV and dengue virus, another case of mpox in Britian, the Marburg virus outbreak in Rwanda, before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, if there is a benefit to additional COVID vaccinations after the initial series, ISDA guideline for using anti-SARS-CoV-2 monoclonal antibody therapy for prophylaxis, where to find PEMGARDA, a reminder of how and when to use steroids to treat COVID-19, if and how do severe secondary bacterial infections develop following SARS-CoV-2 infection, and if COVID-19 associates with a risk of autoimmune and autoinflammatory connective tissue disorders.
Subscribe (free): Apple Podcasts, RSS, email
Become a patron of TWiV!
Links for this episodeIntro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv